SEARCH:   Advanced

Blood, 1 September 2008, Vol. 112, No. 5, pp. 2120-2128. Prepublished online as a Blood First Edition Paper on June 13, 2008; DOI 10.1182/blood-2007-07-100222. This Article Full Text Full Text (PDF) Supplemental Table and Figure All Versions of this Article: blood-2007-07-100222v1 112/5/2120    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mullighan, C. G. Articles by Bardy, P. G. Search for Related Content PubMed PubMed Citation Articles by Mullighan, C. G. Articles by Bardy, P. G. Related Collections Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation Charles G. Mullighan13, Susan L. Heatley2, Silke Danner2, Melinda M. Dean4, Kathleen Doherty2, Uwe Hahn1, Kenneth F. Bradstock5, Robyn Minchinton4, Anthony P. Schwarer6, Jeff Szer7, and Peter G. Bardy1,2 1 Institute of Medical and Veterinary Science, Adelaide, Australia; 2 Research and Development, Australian Red Cross Blood Service, Adelaide, Australia; 3 St Jude Children's Research Hospital, Memphis, TN; 4 Cooperative Research Centre for Vaccine Technology at the Australian Red Cross Blood Service, Brisbane, Australia; 5 Westmead Hospital, Sydney, Australia; 6 The Alfred Hospital, Melbourne, Australia; and 7 Royal Melbourne Hospital, Melbourne, Australia Mannose-binding lectin (MBL) is a mediator of innate immunity that influences the risk of infection in a range of clinical settings. We previously reported associations between MBL2 genotype and infection in a retrospective study of myeloablative allogeneic hematopoietic stem cell transplantation (allo-HCT). However, other studies have been inconclusive, and the role of MBL in reduced-intensity conditioning (RIC) transplantation is unknown. Here we report a prospective study examining MBL2 genotype, MBL levels, and risk of major infection following HLA-matched sibling myeloablative (n = 83) and RIC (n = 59) HCT. Baseline MBL levels were higher in recipients than donors (P < .001), and recipient MBL levels increased during the peritransplantation period (P = .001), most notably in MBL2 wild-type individuals receiving myeloablative total body irradiation (mTBI). MBL2 coding mutations were associated with major infection in recipients receiving mTBI. The cumulative incidence of major infection in recipient harboring an MBL2 mutation receiving mTBI was 70.6%, compared with 31.1% of those without mutations not receiving mTBI (P = .01). MBL status was not associated with infection in RIC transplants. These results confirm the association of MBL status with risk of infection in myeloablative, TBI-conditioned transplantation. Studies examining the role of MBL replacement therapy to prevent infection in this setting should be considered. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020